A study of persistent remission using ivosidenib in relapsed or refractory AML with IDH1 mutations showed that in (125 rate complete remission partial hematologic recovery was 30.4% (95% CI, 22.5–39.3), 21.6% CI, 14.7–29.8), overall response 41.6% 32.9–50.8) (DiNardo et al., 2018). This evidence concerns the gene IDH1 and acute myeloid leukemia.